Human papillomavirus prophylactic vaccines: stakes and perspectives;Vaccins prophylactiques antipapillomavirus : enjeux et perspectives

Gynecologie Obstetrique et Fertilite

Volumn 34, Issue 7-8, 2006, Pages 647-655

  Hantz, S ^a   Alain, S ^a   Denis, F ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

Cervical Cancer; Human papillomavirus; Vaccine; VLP

Indexed keywords

WART VIRUS VACCINE; PAPILLOMA VIRUS VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

ANTIBODY TITER; ARTICLE; CANCER GROWTH; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CONDYLOMA; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; INFECTION PREVENTION; PERSISTENT INFECTION; PRECANCER; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; VIRUS ETIOLOGY; VIRUS PARTICLE; WART VIRUS; ADOLESCENT; ADULT; BLOOD; CHILD; FEMALE; GENETICS; GYNECOLOGIC DISEASE; IMMUNOLOGY; PAPILLOMA VIRUS; REVIEW; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CHILD; FEMALE; GENITAL DISEASES, FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRECANCEROUS CONDITIONS; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 33747038742     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/j.gyobfe.2006.05.008     Document Type: Article

References (27)

1. o°5. Version 2.0 (2004), IARC Press, Lyon
2. Beby-Defaux A., and Agius G. Papillomaviridae. In: Huraux J.M., Nicolas J.C., Agut H., and Peigue-Lafeuille H. (Eds). Traité de virologie médicale (2003), Estem, Paris 267-273
3. Douvier S, Dalac S. -Infections à papillomavirus.- Encycl. Méd. Chir., Maladies infectieuses. 2004;8-054-A-10, 19 p.
4. Hebner C.M., and Laimins L.A. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev. Med. Virol. 16 (2006) 83-97
5. Dalstein V., Prétet J.L., and Mougin C. Histoire naturelle de l'infection à HPV muqueux. In: Aubin F., Prétet J.L., and Mougin C. (Eds). Papillomavirus humains. Biologie et pathologie tumorale (2003), Editions TEC & DOC, Paris 287-307
6. Bozon M. À quel âge les femmes et les hommes commencent-ils leur vie sexuelle ? Comparaison mondiale et évolution récente. Popul. Soc. (Paris) 391 (2003) 1-4
7. Boulanger J.C., Sevestre H., Bauville E., Ghighi C., Harlicot J.P., and Gondry J. Épidémiologie de l'infection à HPV. Gynecol. Obstet. Fertil. 32 (2004) 218-223
8. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J. Natl. Cancer Inst. 87 (1995) 796-802
9. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189 (1999) 12-19
10. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., and Shah K.V. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55 (2002) 244-265
11. Bosch F.X. Épidémiologie des infections à HPV de type muqueux. In: Aubin F., Prétet J.L., and Mougin C. (Eds). Papillomavirus humains. Biologie et pathologie tumorale (2003), Editions TEC & DOC, Paris 335-357
12. e édition (2004), Elsevier, Philadelphia 1259-1265
13. Hagensee M., Yaegashi N., and Galloway D. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J. Virol. 67 (1993) 315-322
14. Rose R.C., Reichmann R.C., and Bonnez W. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J. Gen. Virol. 75 (1994) 2075-2079
15. Munoz N., Bosch F.X., Castellsague X., Diaz M., de Sanjose S., Hammouda D., et al. Against which human papilomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer 111 (2004) 278-285
16. Nardelli-Haefliger D., Wirthmer D., Schiller J.T., Lowy D.R., Hildesheim A., Ponci F., et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 Virus-like particles. J. Natl. Cancer Inst. 95 (2003) 1128-1137
17. Mao C., Koutsky L., Ault K., Wheeler C., Brown D.M., Wiley D., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol. 107 (2006) 18-27
18. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6 (2005) 271-278
19. Koff R.S. Immunogenicity of hepatitis B vaccines: implications of immune memory. Vaccine (2002) 3695-3701
20. Munoz N. A review of the phase III clinical data for the quadrivalent human papillomavirus vaccine. Eurogin (2006) 23-26
21. Harper D.M., Franco E.L., Wheeler C., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
22. Combita A.L., Touze A., Bousarghin L., Christensen N.D., and Coursaget P. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J. Virol. 76 (2002) 6480-6486
23. Mendez F., Munoz N., Posso H., Molano M., Moreno V., and van den Brule A.J.C. Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines. J. Infect. Dis. 192 (2005) 1158-1165
24. Taira A.V., Neukermans C.P., and Sanders G.D. Evaluating human papillomavirus vaccination programs. Emerg. Infect. Dis. 10 (2004) 1915-1923
25. Anttila A., Ronco G., Clifford G., Bray F., Hakama M., Arbyn M., et al. Cervical cancer screening programmes and policies in 18 European countries. Br. J. Cancer 91 (2004) 935-941
26. van Ballegooijen M., and Hermens R. Cervical cancer screening in the Netherlands. Eur. J. Cancer 36 (2000) 2244-2246
27. Kyrgiou M., Koliopoulos G., Martin-Hirsch P., Arbyn M., Prendiville W., and Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 367 (2006) 89-98